source
- Lilly's mid‑stage weight‑loss trial looms as amylin design becomes a key differentiatorThe pharmaceutical community is watching a growing debate over how best to design amylin‑based medicines. Analysts say that the structural choices made by companies could determine which candidates…
- Experts split over Huidagene’s gene-editing approach after boy’s death in Duchenne trialA young boy died while participating in Huidagene’s gene‑editing trial for Duchenne muscular dystrophy, raising serious questions about the company’s experimental strategy. STAT+ reviewed video of…